Eli Lilly & Co (LLY) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LLY Analyst Ratings

Strong Buy

19 Buy

2 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

$23,652.60

Based on 21 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is $23,652.60 with a high forecast of $28,014.15 and a low forecast of $19,872.54. The average price target represents a ― change from the last price of ―.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13560":"$13,560","28015":"$28,015","17173.75":"$17,173.8","20787.5":"$20,787.5","24401.25":"$24,401.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":28014.147152,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$28K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23652.602465473152,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19872.53563595,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13560,17173.75,20787.5,24401.25,28015],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20827.689,21380.493473230767,21933.29794646154,22486.102419692306,23038.906892923078,23591.711366153846,24144.515839384614,24697.320312615386,25250.124785846154,25802.929259076926,26355.733732307694,26908.53820553846,27461.34267876923,{"y":28014.147152,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20827.689,21044.990035805626,21262.291071611253,21479.59210741688,21696.893143222507,21914.194179028134,22131.49521483376,22348.79625063939,22566.097286445016,22783.398322250643,23000.69935805627,23218.000393861897,23435.301429667525,{"y":23652.602465473152,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20827.689,20754.215664303843,20680.742328607692,20607.268992911537,20533.795657215385,20460.32232151923,20386.848985823075,20313.375650126924,20239.90231443077,20166.428978734613,20092.955643038462,20019.482307342307,19946.008971646155,{"y":19872.53563595,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14462.948,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14367.74,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 79,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13561.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 70,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15092.177,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 73,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15970.537,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19340.559,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19354.61,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18081.331,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17569.639,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17079.377,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16318.521,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18707.009,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 87,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20827.689,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$28,014

Average Price Target$23,653

Lowest Price Target$19,873

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evan Seigerman

BMO Capital

$22,761.49

Buy

―

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Atricure (NASDAQ: ATRC)

Courtney Breen

Bernstein

$24,249.75

Buy

―

Reiterated

07/22/26

Eli Lilly & Co (LLY) Receives a Buy from Bernstein

Trung Huynh

RBC Capital

$26,263.26

Buy

―

Reiterated

07/21/26

David Risinger

Leerink Partners

―

Buy

―

Reiterated

07/17/26

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)

Emily Field

Barclays

$24,512.38

Buy

―

Assigned

07/17/26

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Kerry Holford

Berenberg Bank

$19,872.54

Hold

―

Reiterated

07/16/26

Eli Lilly & Co (LLY) Gets a Hold from Berenberg Bank

Geoff Meacham

Citi

$26,263.26→$28,014.15

Buy

―

Reiterated

07/15/26

Eli Lilly price target raised to $1,600 from $1,500 at CitiEli Lilly price target raised to $1,600 from $1,500 at Citi

Seamus Fernandez

Guggenheim

$21,623.42→$22,288.76

Buy

―

Assigned

07/13/26

Eli Lilly price target raised to $1,273 from $1,235 at GuggenheimEli Lilly price target raised to $1,273 from $1,235 at Guggenheim

Michael Yee

UBS

$21,886.05→$24,950.1

Buy

―

Assigned

07/13/26

Eli Lilly price target raised to $1,425 from $1,250 at UBSEli Lilly price target raised to $1,425 from $1,250 at UBS

Jason Gerberry

Bank of America Securities

$21,903.56→$23,356.8

Buy

―

Assigned

07/10/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Eli Lilly & Co (NYSE: LLY)

Mohit Bansal

Wells Fargo

$22,411.32

Buy

―

Reiterated

07/10/26

Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

$22,428.83→$23,987.11

Buy

―

Reiterated

07/09/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Eli Lilly & Co (NYSE: LLY)

Terence Flynn

Morgan Stanley

$23,531.88→$23,584.41

Buy

―

Reiterated

07/08/26

Eli Lilly price target raised to $1,347 from $1,344 at Morgan StanleyEli Lilly price target raised to $1,347 from $1,344 at Morgan Stanley

Chris Schott

J.P. Morgan

$22,761.49→$24,512.38

Buy

―

Assigned

07/07/26

Eli Lilly Price Target Raised to $1,400 on Incretin Leadership, Obesity Growth, and Robust 2026 Outlook

Akash Tewari

Jefferies

$23,636.94

Buy

―

Reiterated

07/06/26

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), AxoGen (NASDAQ: AXGN) and Eli Lilly & Co (NYSE: LLY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evan Seigerman

BMO Capital

$22,761.49

Buy

―

Reiterated

07/23/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Atricure (NASDAQ: ATRC)

Courtney Breen

Bernstein

$24,249.75

Buy

―

Reiterated

07/22/26

Eli Lilly & Co (LLY) Receives a Buy from Bernstein

Trung Huynh

RBC Capital

$26,263.26

Buy

―

Reiterated

07/21/26

David Risinger

Leerink Partners

―

Buy

―

Reiterated

07/17/26

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)

Emily Field

Barclays

$24,512.38

Buy

―

Assigned

07/17/26

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

Kerry Holford

Berenberg Bank

$19,872.54

Hold

―

Reiterated

07/16/26

Eli Lilly & Co (LLY) Gets a Hold from Berenberg Bank

Geoff Meacham

Citi

$26,263.26→$28,014.15

Buy

―

Reiterated

07/15/26

Eli Lilly price target raised to $1,600 from $1,500 at CitiEli Lilly price target raised to $1,600 from $1,500 at Citi

Seamus Fernandez

Guggenheim

$21,623.42→$22,288.76

Buy

―

Assigned

07/13/26

Eli Lilly price target raised to $1,273 from $1,235 at GuggenheimEli Lilly price target raised to $1,273 from $1,235 at Guggenheim

Michael Yee

UBS

$21,886.05→$24,950.1

Buy

―

Assigned

07/13/26

Eli Lilly price target raised to $1,425 from $1,250 at UBSEli Lilly price target raised to $1,425 from $1,250 at UBS

Jason Gerberry

Bank of America Securities

$21,903.56→$23,356.8

Buy

―

Assigned

07/10/26

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Eli Lilly & Co (NYSE: LLY)

Mohit Bansal

Wells Fargo

$22,411.32

Buy

―

Reiterated

07/10/26

Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

$22,428.83→$23,987.11

Buy

―

Reiterated

07/09/26

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (NASDAQ: ALNY) and Eli Lilly & Co (NYSE: LLY)

Terence Flynn

Morgan Stanley

$23,531.88→$23,584.41

Buy

―

Reiterated

07/08/26

Eli Lilly price target raised to $1,347 from $1,344 at Morgan StanleyEli Lilly price target raised to $1,347 from $1,344 at Morgan Stanley

Chris Schott

J.P. Morgan

$22,761.49→$24,512.38

Buy

―

Assigned

07/07/26

Eli Lilly Price Target Raised to $1,400 on Incretin Leadership, Obesity Growth, and Robust 2026 Outlook

Akash Tewari

Jefferies

$23,636.94

Buy

―

Reiterated

07/06/26

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), AxoGen (NASDAQ: AXGN) and Eli Lilly & Co (NYSE: LLY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AORTArtivion

ENOVEnovis

GKOSGlaukos

IFRXInflaRx

BKDBrookdale Senior Living

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months

Louise ChenScotiabank

Success Rate

28/36 ratings generated profit

Average Return

+9.65%

Copying Louise Chen's trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +9.65% per trade.

1 Year

Geoff MeachamCiti

Success Rate

43/44 ratings generated profit

Average Return

+43.05%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 97.73% of your transactions generating a profit, with an average return of +43.05% per trade.

2 Years

Louise ChenScotiabank

Success Rate

36/36 ratings generated profit

Average Return

+79.74%

Copying Louise Chen's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +79.74% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LLY has received 75 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. LLY average Analyst price target in the past 3 months is 23,652.60.

Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is $105.16 with a range of $92.45 to $115.87. The previous quarter’s EPS was $149.70. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is $362.17B with a range of $353.56B to $377.49B. The previous quarter’s sales results were $346.66B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Stock Forecast FAQ

What is MX:LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly And Company’s 12-month average price target is 23,652.60.

What is MX:LLY’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MX:LLY, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eli Lilly And Company a Buy, Sell or Hold?

Eli Lilly And Company has a consensus rating of Strong Buy, which is based on 19 buy ratings, 2 hold ratings and 0 sell ratings.

What is Eli Lilly And Company’s share price target?

The average share price target for Eli Lilly And Company is 23,652.60. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $28,014.15 ,and the lowest forecast is $19,872.54. The average share price target represents N/A Increase from the current price of N/A.

What do analysts say about Eli Lilly And Company?

Eli Lilly And Company’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Eli Lilly And Company?

To buy shares of MX:LLY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Eli Lilly & Co (LLY) Stock Forecast & Price Target

LLY Analyst Ratings

LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

LLY Analyst Recommendation Trends

LLY Financial Forecast

LLY Earnings Forecast

LLY Sales Forecast

LLY Stock Forecast FAQ

Detailed List of Analyst Forecasts